NCT03705507 - International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 18, 2018

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia Recurrent

Interventions

DRUG

Selumetinib

Selumetinib is a small molecule inhibitor of the MEK protein

DRUG

Dexamethasone

Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.

Trial Locations (17)

DK-2100

Rigshospitalet, Copenhagen

3584 CS

Prinses Maxima Centrum Voor Kinderoncologie, Utrecht

B15 2TH

Queen Elizabeth Hospital, Birmingham

B4 6NH

Birmingham Children's Hospital, Birmingham

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

L12 2AP

Alder Hey Children's Hospital, Liverpool

NW1 2PG

University College Hospital Adult Unit, London

University College Hospital Paediatric/Teenage & Young Adult Unit, London

SE5 9RS

King's College Hospital, London

W12 0HS

Hammersmith Hospital, London

WC1N 3JH

Great Ormond Street Hospital, London

M20 4BX

The Christie Hospital, Manchester

NE1 4LP

Great North Children's Hospital, Royal Victoria Infirmary, Newcastle

NE7 7DN

Freeman Hospital, Newcastle

S10 2JF

Royal Hallamshire Hospital, Sheffield

SM2 5PT

Department of Paediatric Oncology, Royal Marsden Hospital, Sutton, Sutton

Haemato-Oncology Adult Unit, Royal Marsden Hospital, Sutton, Sutton